Caribou Biosciences (NASDAQ: CRBU) insider transactions
In the twelve months to 10 November 2026, executives and directors of Caribou Biosciences reported 5 open-market sales of 24,317 shares ($47,474) and 0 open-market purchases, by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 25 February 2026 | Kelly Timothy P | Chief Technology Officer | Open-market sale | −6,228 | $1.93 | 73,125 | Form 4 |
| 24 February 2026 | McClung Barbara G | Chief Legal Officer | Open-market sale | −6,938 | $1.96 | 481,564 | Form 4 |
| 24 February 2026 | Kelly Timothy P | Chief Technology Officer | Open-market sale | −3,147 | $1.96 | 79,353 | Form 4 |
| 24 February 2026 | Khan Ruhi Ahmad | Chief Business Officer | Open-market sale | −6,938 | $1.96 | 104,998 | Form 4 |
| 24 February 2026 | Albertson Tina M. | Chief Medical Officer | Open-market sale, 10b5-1 plan | −1,066 | $1.96 | 68,523 | Form 4 |
| 20 February 2026 | McClung Barbara G | Chief Legal Officer | Grant or award | +45,000 | — | 488,502 | Form 4 |
| 20 February 2026 | Kelly Timothy P | Chief Technology Officer | Grant or award | +45,000 | — | 82,500 | Form 4 |
| 20 February 2026 | Khan Ruhi Ahmad | Chief Business Officer | Grant or award | +45,000 | — | 111,936 | Form 4 |
| 20 February 2026 | Albertson Tina M. | Chief Medical Officer | Grant or award, 10b5-1 plan | +55,000 | — | 69,589 | Form 4 |
| 20 February 2026 | Haurwitz Rachel E. | President and CEO | Grant or award | +151,700 | — | 447,150 | Form 4 |
| 20 February 2026 | Ryali Sriram | Chief Financial Officer | Grant or award | +55,000 | — | 72,360 | Form 4 |
| 14 March 2025 | Haurwitz Rachel E. | President and CEO | Open-market purchase | +20,000 | $1.02 | 3,369,395 | Form 4 |
| 21 February 2025 | McClung Barbara G | Chief Legal Officer | Open-market sale | −3,564 | $1.35 | 443,502 | Form 4 |
| 21 February 2025 | Kanner Steven | Chief Scientific Officer | Open-market sale | −3,564 | $1.35 | 431,556 | Form 4 |
| 21 February 2025 | Khan Ruhi Ahmad | Chief Business Officer | Open-market sale | −3,564 | $1.35 | 66,936 | Form 4 |
| 20 February 2025 | McClung Barbara G | Chief Legal Officer | Grant or award | +37,500 | — | 447,066 | Form 4 |
| 20 February 2025 | Haurwitz Rachel E. | President and CEO | Grant or award | +136,750 | — | 295,450 | Form 4 |
| 20 February 2025 | Kelly Timothy P | Chief Technology Officer | Grant or award | +37,500 | — | 37,500 | Form 4 |
| 20 February 2025 | Kanner Steven | Chief Scientific Officer | Grant or award | +37,500 | — | 435,120 | Form 4 |
| 20 February 2025 | Khan Ruhi Ahmad | Chief Business Officer | Grant or award | +37,500 | — | 70,500 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Caribou Biosciences page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.